FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request

Based on its fiscal 2017 budget justification, FDA does not support a congressional proposal to formalize Cosmetic Ingredient Review safety assessments through a public-private partnership. The agency still intends to prepare a report on the subject, as directed by Senate and House appropriations committees, but characterizes the proposed framework as "inappropriate."

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

More from HBW Insight